Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2014-12-30 Declaration of Voting R…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It reports the results of the Annual General Meeting (AGM) held on December 30, 2014, including approvals of auditor appointment, director elections, and other shareholder resolutions. The content focuses on announcements made at the AGM rather than the full AGM materials or presentations. The document length is about 5,454 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is the announcement of AGM results, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not a full Annual Report (10-K), nor a Management Report (MDA), nor an Investor Presentation (IP). Therefore, the best classification is DVA with high confidence.
2014-12-30 Hebrew (modern)
Other Report or Announcement
AGM Information Classification · 98% confidence The document explicitly states: "Attached hereto is a report on *Annual General Meeting Results.*". This directly corresponds to the definition of AGM Information (Code: AGM-R). Although it is a short announcement referencing an attached PDF, the specific nature of the content (AGM Results) makes AGM-R a more precise classification than the general RPA or RNS fallback. The document is an announcement of the results of the Annual General Meeting.
2014-12-30 English
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports the results of the company's Annual General Meeting (AGM) held on December 30, 2014, including approvals of auditor appointment, director elections, and other shareholder resolutions. The content focuses on the announcement of AGM outcomes rather than the full AGM materials or presentations. The document length is 5599 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting.
2014-12-30 English
Immediate Report
Regulatory Filings
2014-12-08 Hebrew (modern)
Immediate Report
Board/Management Information Classification · 98% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations). The key content states: 'Attached hereto is a report on *appointment of Dr. Jonathan Schapiro and Dr. Dobroslav Melamed to the Board.*'. This explicitly announces a change in the Board of Directors. According to the definitions, the category for announcement of changes in the company's board of directors or senior management is 'Board/Management Information' (MANG). Although it mentions an attachment, the core subject is the management change, making MANG more specific than the general RPA or RNS fallback.
2014-12-08 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports a change in director positions, specifically the appointment of two new board members. The document includes a press release as an exhibit announcing these appointments. There is no detailed financial data, earnings information, or comprehensive report content. The primary focus is on management/board changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 4245 characters, which is relatively short but contains substantive information about management changes, not just a report publication announcement or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2014-12-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.